Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new research reveals.

Genomic cancer predisposition tests should be done with professional counseling, and the FDA should implement safeguards for ...

A local radio host is encouraging Tucsonans to consider genetic testing after it played a critical role in her own health ...

A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...

Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.